Meports turns passive wearable data into clinical intelligence for GLP-1 telehealth platforms — so your clinicians see what's happening between visits and your patients stay longer.
Integration docs + pricing sent within 48hrs. No spam.
You prescribe, ship, and check in once a month. Between visits, you have zero visibility into patient status. The $2-3B GLP-1 telehealth market is a sea of prescription vending machines.
Patients disengage weeks before they cancel. By the time you notice, they're gone. Only 32% persist at one year.
Dose escalation based on "how do you feel?" instead of continuous HRV, sleep, and activity data. Only 23% reach optimal dose.
Up to 45% of GLP-1 weight loss can be muscle. You can't detect it from a monthly self-reported weigh-in.
78% of patients are willing to share wearable data, but only 26.5% actually do. The willingness-action gap is a UX problem.
FDA enforcement ended compounding. New orals at $149/mo mean price parity. The battleground shifts to outcomes and retention.
75% of lost weight rebounds after discontinuation. Without monitoring, you can't intervene before significant regain.
Patients wear their devices like normal. We surface actionable signals to your clinicians and care ops team.
HRV stability, sleep quality, and resting HR trends across dose tiers. Know when a patient is ready to step up — or needs to hold.
GI distress manifests as sleep disruption and HRV drops before patients self-report. Catch it at day 3, not week 4.
Declining activity, irregular sleep, missed check-ins. Engagement risk scored and outreach triggered before the cancel click.
Exercise capacity, resting metabolic indicators, activity tolerance tracked over time. Flag patients losing muscle, not just weight.
White-label SDK that drops into your existing patient app. Webhook-based signal delivery to your stack.
One-tap OAuth in your existing onboarding. We handle all device APIs and auth flows.
HR, HRV, sleep stages, activity, SpO2 — continuous, normalized across all devices.
Titration readiness, side effects, churn risk — delivered to your EHR or care dashboard.
Optional white-label dashboard turning wearable data into a GLP-1 journey view.
FDA enforcement ended compounding. Branded orals launched at $149/mo. Price parity means retention is the only lever left.
Estimated 2025 revenue across all platforms. Growing toward $8-12B by 2030.
Extending average tenure from 6 to 9 months at $199/mo ARPU.
Each additional percent of weight loss reduces discontinuation hazard. Better outcomes = better retention.
Everything you need to add continuous patient intelligence without building a wearable integration team.
Apple Watch
Oura Ring
Fitbit
WHOOPWe're onboarding a small number of GLP-1 platforms for our initial pilot. Drop your email and we'll send integration docs and pricing.
Pilot spots limited · Response within 48hrs